Matriptase-2 Inhibitors for Hepcidin Regulation in IRIDA
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for iron-refractory iron deficiency anemia (IRIDA) due to mutations in matriptase-2 are inadequate, as they do not effectively address the underlying issue of inappropriate hepcidin levels caused by matriptase-2 activity.
Innovation Solution
Development of compounds that inhibit matriptase-2 activity, thereby increasing hepcidin production to regulate iron metabolism and treat conditions associated with relative or absolute hepcidin deficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If matriptase-2 activity is left unchecked, then iron metabolism is disrupted and hepcidin levels become inappropriately high, but current treatments do not effectively address the underlying issue
Solution Approach 1:
The patent extracts and targets the specific enzymatic activity of matriptase-2 that is causing the problem. By developing inhibitors that specifically block matriptase-2's proteolytic activity, the treatment directly addresses the root cause of inappropriate hepcidin levels rather than treating symptoms, thereby improving treatment effectiveness.
Solution Approach 2:
The patent changes the functional state of matriptase-2 from active to inhibited through chemical compounds. The inhibitors alter the enzyme's activity parameter, transforming it from a state that produces harmful hepcidin levels to a state that allows appropriate hepcidin regulation, thus resolving the treatment effectiveness issue.
2Reliability
If matriptase-2 activity is inhibited, then hepcidin production increases and iron metabolism is regulated, but the compounds must be specifically designed to target matriptase-2
Solution Approach 1:
The patent develops a class of inhibitors that can target matriptase-2 and potentially other matriptase family members. By creating a universal inhibitory mechanism that works across the matriptase family, the treatment can regulate iron metabolism effectively while the compound design complexity is managed through a systematic approach to inhibitor development.
Solution Approach 2:
The patent systematically varies chemical parameters of the inhibitor compounds to optimize their binding affinity and specificity for matriptase-2. By adjusting molecular structure, binding sites, and interaction mechanisms, the compounds achieve effective inhibition without requiring overly complex designs, thus balancing regulation effectiveness with design feasibility.
3Productivity
If existing treatments are used for IRIDA, then some therapeutic effect is achieved, but they do not effectively address the underlying matriptase-2 activity
Solution Approach 1:
The patent extracts the root cause (matriptase-2 activity) from the complex picture of IRIDA pathophysiology and targets it directly. By removing or inhibiting this specific enzymatic activity, the treatment achieves both therapeutic effect and addresses the underlying cause, thereby improving reliability compared to treatments that only address symptoms.
Solution Approach 2:
Instead of treating the consequences of matriptase-2 activity (high hepcidin levels, iron deficiency), the patent inverts the approach by directly inhibiting matriptase-2 itself. This inverted strategy allows the body's natural hepcidin production to function correctly, achieving both therapeutic effect and root cause treatment simultaneously.
Data Source
AI summary
The present invention provides compounds for inhibiting matriptase 2, or a mutant thereof, and compositions and methods of use thereof.